Triapine
Names
[ CAS No. ]:
143621-35-6
[ Name ]:
Triapine
[Synonym ]:
2-[(3-Amino-2-pyridinyl)methylene]hydrazinecarbothioamide
2-[(3-Aminopyridin-2-yl)methylene]hydrazinecarbothioamide
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP PAN-811
(2E)-2-[(3-Amino-2-pyridinyl)methylene]hydrazinecarbothioamide
Hydrazinecarbothioamide, 2-[(3-amino-2-pyridinyl)methylene]-
Biological Activity
[Description]:
[Related Catalog]:
[Target]
Ribonucleotide reductase (RR)[1]
[In Vitro]
[In Vivo]
[Cell Assay]
[Animal admin]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.5±0.1 g/cm3
[ Boiling Point ]:
436.0±55.0 °C at 760 mmHg
[ Melting Point ]:
234°C(lit.)
[ Molecular Formula ]:
C7H9N5S
[ Molecular Weight ]:
195.245
[ Flash Point ]:
217.5±31.5 °C
[ Exact Mass ]:
195.057861
[ PSA ]:
125.95000
[ LogP ]:
0.98
[ Appearance of Characters ]:
white to light brown
[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C
[ Index of Refraction ]:
1.720
[ Storage condition ]:
2-8°C
[ Water Solubility ]:
DMSO: soluble10Meq/mL, clear
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H315-H319-H335
[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338
[ Hazard Codes ]:
Xn
[ Risk Phrases ]:
22-36/37/38
[ Safety Phrases ]:
26
[ RIDADR ]:
UN 2811 6.1 / PGIII
[ HS Code ]:
2933990090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933990090
[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Exp. Parasitol. 150 , 7-12, (2015)
Only a few drugs are available for treating sleeping sickness and nagana disease; parasitic infections caused by protozoans of the genus Trypanosoma in sub-Saharan Africa. There is an urgent need for ...
Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.Antioxid. Redox Signal. 18(8) , 956-72, (2013)
Despite advances made in the treatment of cancer, a significant number of patients succumb to this disease every year. Hence, there is a great need to develop new anticancer agents.Emerging data show ...
Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.Cancer Res. 75 , 2863-74, (2015)
Generalized strategies to improve breast cancer treatment remain of interest to develop. In this study, we offer preclinical evidence of an important metabolic mechanism underlying the antitumor activ...